Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity
Peter J. Holst, … , Thue W. Schwartz, Sergio A. Lira
Peter J. Holst, … , Thue W. Schwartz, Sergio A. Lira
Published December 15, 2001
Citation Information: J Clin Invest. 2001;108(12):1789-1796. https://doi.org/10.1172/JCI13622.
View: Text | PDF
Article

Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity

  • Text
  • PDF
Abstract

ORF74 (or KSHV-vGPCR) is a highly constitutively active G protein–coupled receptor encoded by HHV8 that is regulated both positively and negatively by endogenous chemokines. When expressed in transgenic mice, this chemokine receptor induces an angioproliferative disease closely resembling Kaposi sarcoma (KS). Here we demonstrate that several lines of mice carrying mutated receptors deficient in either constitutive activity or chemokine regulation fail to develop KS-like disease. In addition, animals expressing a receptor that preserves chemokine binding and constitutive activity but that does not respond to agonist stimulation have a much lower incidence of angiogenic lesions and tumors. These results indicate that induction of the KS-like disease in transgenic mice by ORF74 requires not only high constitutive signaling activity but also modulation of this activity by endogenous chemokines.

Authors

Peter J. Holst, Mette M. Rosenkilde, Denise Manfra, Shu-Cheng Chen, Maria T. Wiekowski, Birgitte Holst, Felix Cifire, Martin Lipp, Thue W. Schwartz, Sergio A. Lira

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Expression of ORF74 and chemokines within lesions of transgenic mice. RT...
Expression of ORF74 and chemokines within lesions of transgenic mice. RT-PCR analysis of distinct CXC chemokines and ORF74 in control and transgenic tissues. ORF74 expression is detected in all transgenic samples, but not in control tissue. Expression of the ELR-chemokines KC and MIP-2 is detected within tumors of CDVG and R2H mice and in inflammatory lesions of Δ22 transgenic mice. The non-ELR chemokines SDF-1α and IP-10 are expressed in both transgenic and control samples.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts